David A. Siegel Compass Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 51,000 shares of CMPX stock, worth $125,460. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,000
Previous 86,400
40.97%
Holding current value
$125,460
Previous $158,000
53.8%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CMPX
# of Institutions
89Shares Held
93.2MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA22.4MShares$55 Million0.88% of portfolio
-
Blackstone Inc New York, NY10MShares$24.7 Million0.07% of portfolio
-
Bio Impact Capital LLC Cambridge, MA8.57MShares$21.1 Million1.86% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$16.3 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.99MShares$14.7 Million0.02% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $249M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...